Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TriSalus Life Sciences, Inc. filings document operating results, governance actions and capital-structure matters for an oncology-focused medical technology company. Form 8-K reports cover financial results, business updates, guidance, material events, leadership changes, board composition and Regulation FD disclosures tied to TriNav, PEDD and related oncology development activity.
Proxy materials describe shareholder voting matters, director elections, board committees, executive compensation and equity awards. The filing record also includes capital-structure disclosures for common stock and warrants, material-agreement categories, clinical or regulatory disclosure topics and risk-related information associated with commercializing PEDD infusion systems and developing investigational therapies for solid tumors.
TriSalus Life Sciences, Inc. filed a current report to note that on August 12, 2025 it issued a press release providing a business update and announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is treated as furnished, not filed, under securities laws, which limits its use in certain types of investor lawsuits and in other company filings unless specifically incorporated by reference.
TriSalus Life Sciences, Inc. (TLSI) filed a Form 4 on 27-Jun-2025 for director Arjun J. Desai. On 12-Jun-2025 Desai received a grant of 15,000 non-qualified stock options at an exercise price of $5.50 per share. The options will fully vest on the earlier of (i) 12-Jun-2026 or (ii) the company’s next annual shareholder meeting, subject to continued service. They expire on 11-Jun-2035. After this grant, Desai beneficially owns 65,000 derivative securities; no common shares were acquired or sold, and ownership remains direct. The filing represents routine director compensation and does not disclose any open-market transactions.
Form 4 filing overview: On June 12 2025, TriSalus Life Sciences, Inc. (TLSI) granted Director Gary B. Gordon a non-qualified stock option covering 15,000 shares of common stock at an exercise price of $5.50 per share. The option expires on June 11 2035.
Vesting terms: The option will become fully vested on the earlier of (i) the one-year anniversary of the grant date (June 12 2026) or (ii) the date of TLSI’s next annual stockholder meeting, provided Mr. Gordon remains in service through such date.
Post-transaction ownership: Following the grant, Mr. Gordon beneficially owns 56,250 derivative securities (stock options) in TLSI, all held directly. No changes in non-derivative share ownership were reported.
Key takeaways for investors: • This is a routine incentive grant to a board member, aligning director compensation with shareholder interests.
• No open-market purchases or sales were disclosed; therefore, the filing does not signal immediate sentiment regarding TLSI’s current share price.
• The grant size is modest and is unlikely to have a material impact on the company’s capitalization or insider ownership structure.